Substituted bicyclic beta-lactams of Formula I: (I) are .beta.-lactamase inhibitors wherein a X R1 and R2 are defined herein.The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with .beta.-lactam antibiotics.In particular the compounds can be employed with a .beta.-lactam antibiotics (e.g. imipenem piperacillin or ceftazidime) against microorganisms resistant to .beta.-lactam antibiotics due to the presence of the .beta.-...

The present invention relates to a new crystalline aminothiazole derivative represented by the following formula (I) which is very useful for the preparation of cephalosporin antibiotics including ceftazidime and cefixime etc: wherein R1 and R2 are the same or different and independently represent H an alkyl group of 1 to 4 carbon atoms or a cycloalkyl group of 3 to 5 carbon atoms X represents chlorine or bromine and the acid in the acid addition salt represents an inorganic acid such as hydroch...

This invention provides novel ?-lactamase inhibitors of the aryl- and heteroarylsulfonamidomethylphosphonate monoester class having nitrogen-based cations or quarternary ammonium groups. The compounds inhibit three classes of ?-lactamases and synergize the antibacterial effects of ?-lactam antibiotics (e.g. imipenem and ceftazidime) against those micro-organisms normally resistant to the ?-lactam antibiotics as a result of the presence of the ?-lactamases. Formula (I) or pharmaceutically accepta...

This invention provides novel [beta]-lactamase inhibitors of the aryl- and heteroarylsulfonamidomethylphosphonate monoester class having nitrogen-based cations or quarternary ammonium groups. The compounds inhibit three classes of [beta]-lactamases and synergize the antibacterial effects of [beta]-lactam antibiotics (e.g., imipenem and ceftazidime) against those micro-organisms normally resistant to the [beta]-lactam antibiotics as a result of the presence of the [beta]-lactamases. Formula (I) o...

A class of 7-oxo-26-diazabicyclo-[3.2.0]-heptane-6-sulfonic acid compounds substituted at the two position of the bicyclic ring with a heterocyclylaminocarbonyl group or a carbocyclylaminocarbonyl group are beta-lactamase inhibitors.The compounds and their prodrugs and pharmaceutically acceptable salts are useful in the treatment of bacterial infections in combination with beta-lactam antibiotics.In particular the compounds are suitable for use with beta-lactam antibiotics (e.g. imipenem and cef...

The disclosure relates to a new pharmaceutical composition comprising: Two different antibiotics and a stabilizing agent suitable for parenteral injection as antimicrobial fixed dose combination therapy for mammals, in dry powder form ready after reconstitution with a suitable solvent for injection, wherein: (a) a first of the antibiotics is a protein synthesis inhibiting antibiotic, selected from a group of aminoglycoside consisting of netilmicin, kanamycin, gentamycin, streptomycin, amikacin, ...